Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE
    • Publication Information:
      Publication: 1995- : Newbury, Berkshire, U.K. : Informa Healthcare
      Original Publication: London, M. D. Promotions, ltd.
    • Subject Terms:
      Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/epidemiology ; Cardiovascular Diseases*/epidemiology ; Cardiovascular Diseases*/prevention & control ; Cardiovascular Diseases*/diagnosis; Humans ; United States/epidemiology ; Hypoglycemic Agents/adverse effects ; Cardiotonic Agents/therapeutic use ; Risk Factors ; Heart Disease Risk Factors ; Glucagon-Like Peptide 1/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists
    • Abstract:
      Objective: To report on the use of antihyperglycemic agents (AHAs) by age (i.e. <65, ≥65 years) in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD) or cardiovascular risk (CV risk) factors in the United States.
      Methods: Patients with T2D and CVD (CVD cohort) or T2D and an additional CV risk factor without pre-existing CVD (CV risk cohort) were identified from 2015 to 2019 in a claims database. Patients were followed from their first observed CVD diagnosis or CV risk factor for each year they were continuously enrolled or until occurrence of a CVD diagnosis (CV risk cohort only). Classes of AHAs received were reported by year, cohort, and age group.
      Results: From 2015 to 2019, the percentage of patients <65 years on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased (CVD: 9-17%, CV risk: 9-17%) and was approximately twice that of those ≥65 years (CVD: 4-8%, CV risk: 4-8%); the percentage of patients <65 years on sodium-glucose cotransporter-2 (SGLT2) inhibitors increased (CVD: 11-16%, CV risk: 11-17%) and was approximately triple that of those ≥65 years (CVD: 3-6%, CV risk: 4-7%).
      Conclusions: The use of GLP-1 RAs and SGLT2 inhibitors increased during the study period; however, most patients did not receive these medications. Patients aged ≥65 years were particularly disadvantaged.
    • Contributed Indexing:
      Keywords: Type 2 diabetes; antihyperglycemic treatment; cardiovascular disease; cardiovascular risk; glucagon-like peptide-1 receptor agonists; sodium-glucose cotransporter-2 inhibitors; treatment patterns
    • Accession Number:
      0 (Hypoglycemic Agents)
      0 (Cardiotonic Agents)
      89750-14-1 (Glucagon-Like Peptide 1)
      0 (Glucagon-Like Peptide-1 Receptor)
    • Publication Date:
      Date Created: 20220627 Date Completed: 20221121 Latest Revision: 20221226
    • Publication Date:
      20231215
    • Accession Number:
      10.1080/03007995.2022.2085962
    • Accession Number:
      35758147